Carrols Restaurant Group, Inc. (TAST) At $12.15 Forms Top; Melinta Therapeutics (MLNT) SI Increased By 68.22%

Melinta Therapeutics Inc (NASDAQ:MLNT) had an increase of 68.22% in short interest. MLNT’s SI was 972,800 shares in March as released by FINRA. Its up 68.22% from 578,300 shares previously. With 177,200 avg volume, 6 days are for Melinta Therapeutics Inc (NASDAQ:MLNT)’s short sellers to cover MLNT’s short positions. The stock increased 4.65% or $0.5 during the last trading session, reaching $11.25. About 659,817 shares traded or 364.74% up from the average. Melinta Therapeutics, Inc. (NASDAQ:MLNT) has 0.00% since March 17, 2017 and is . It has underperformed by 16.70% the S&P500.

Carrols Restaurant Group, Inc. (TAST) formed multiple top with $12.88 target or 6.00% above today’s $12.15 share price. Carrols Restaurant Group, Inc. (TAST) has $430.51 million valuation. The stock increased 1.67% or $0.2 during the last trading session, reaching $12.15. About 465,546 shares traded or 83.57% up from the average. Carrols Restaurant Group, Inc. (NASDAQ:TAST) has risen 0.56% since March 17, 2017 and is uptrending. It has underperformed by 16.14% the S&P500.

Melinta Therapeutics, Inc., an antibiotics company, is engaged in the discovery, development, and commercialization of antibiotics to overcome drug-resistant, life-threatening infections. The company has market cap of $352.64 million. It develops Delafloxacin, a fluoroquinolone for acute bacterial skin and skin structure infections caused by Gram-positive and Gram-negative bacteria; and Baxdela for the treatment of patients with acute bacterial skin and skin structure infections. It currently has negative earnings. Melinta Therapeutics, Inc. was formerly known as formerly Rib-X Pharmaceuticals and changed its name to Melinta Therapeutics, Inc. on October 7, 2013.

Analysts await Carrols Restaurant Group, Inc. (NASDAQ:TAST) to report earnings on May, 8. They expect $-0.17 EPS, down 21.43% or $0.03 from last year’s $-0.14 per share. After $0.08 actual EPS reported by Carrols Restaurant Group, Inc. for the previous quarter, Wall Street now forecasts -312.50% negative EPS growth.

Among 3 analysts covering Carrols Restaurant Group (NASDAQ:TAST), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Carrols Restaurant Group had 5 analyst reports since January 29, 2016 according to SRatingsIntel. The stock has “Buy” rating by Citigroup on Monday, November 20. The firm earned “Outperform” rating on Tuesday, September 26 by Raymond James. The stock has “Buy” rating by Citigroup on Monday, March 5.